Clinical Trial

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

Study acronym: InavoPC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.
Protocol Amendment History 6 changes
notable Trial sites expanded: 39 -> 47 locations 2026-08-06
notable Trial sites expanded: 32 -> 39 locations 2026-07-07
notable Trial sites expanded: 20 -> 32 locations 2026-06-05
notable Trial sites expanded: 13 -> 20 locations 2026-05-07
notable Trial sites expanded: 10 -> 13 locations 2026-04-09
notable Primary completion pushed: 2027-05-14 -> 2028-03-31 2026-04-09
Trial Details
NCT Number NCT07287150
Lead Sponsor Hoffmann-La Roche
Conditions Metastatic Castration-Resistant Prostate Cancer
Enrollment 100 participants
Start Date 2026-03-11
Primary Completion 2028-03-31 (estimated)
Study Completion 2029-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-05